LifeTech Scientific Corporation Announces 2021 Interim Results
PR91391
SHENZHEN, China, Aug. 31, 2021 /PRNewswire=KYODO JBN/ --
LifeTech Scientific Corporation (LifeTech, 01302.HK), a leading company
specialized in minimally invasive interventional medical devices for
cardio-cerebrovascular and peripheral vascular diseases, today announced 2021
interim results.
Compared with the first half of 2020, LifeTech achieved an outstanding
performance. The revenue was approximately RMB461.1 million, increased by
approximately 68.9%, the gross profit and the net profit was recorded
approximately RMB374.4 million and RMB204.4 million respectively, representing
an increase of around 72.5% and 106.5% respectively.
In the first half of 2021, the sales generated from mainland China was
increased by approximately 74.6% and it accounted for approximately 84.0% of
the total revenue. Although the COVID-19 epidemic situation in most overseas
markets remained unstable, the overseas sales still increased by approximately
44.3% as compared with the corresponding period of 2020.
As the performance of business segments, in the first half of 2021, the
turnover contributed by the structural heart diseases business was
approximately RMB159.1 million, representing an increase of approximately
100.6%, of which the sales of LAA occluder increased by approximately 147.5%
and the sales of the three CHD occluders: HeartR™, Cera™ and CeraFlex™
increased by approximately 47.3%,160.0% and 13.3% respectively.
LifeTech's peripheral vascular disease business generated the turnover of
approximately RMB286.8 million, representing an increase of approximately
50.0%, of which the sales of stent grafts and vena cava filters increased by
approximately 60.8% and 24.7% respectively.
The turnover contributed by the cardiac pacing and electrophysiology business
was approximately RMB15.2 million, representing a growth of approximately
508.0%.
LifeTech continuously strengthened its innovation capabilities and accelerated
the R&D process of its pipeline products to maintain its leading position in
the industry, the R&D expenses increased by approximately 25.3% to
approximately RMB91.7 million in the first half of 2021, and achieved the
following main progress:
G-iliac™ Iliac Artery Bifurcation Stent Graft System, LAnavi™ Jointed Steerable
Introducer, Freepath™Guidance System and OKcurve™ Steerable Delivery System
obtained official registration approval from the China NMPA;
Xuper™ Open Surgery Stent Graft System obtained the CE certification in EU;
IBS Angel™ Iron Bioresorbable Scaffold System ("IBS Angel™") obtained
registration approval from Medical Device Authority in Malaysia;
Artery Stent Graft System (chimney graft) was approved as an innovative medical
device in China;
Cinenses™ Lung Volume Reduction Reverser System has completed the enrollment of
clinical trials in Europe;
G-Branch™Thoraco-Abdominal Aortic Stent Graft System has completed the
enrollment of FIM study and the mid-term follow-up results are positive;
LAmbre™ LAA Occluder System, IBS Titan™ Sirolimus-Eluting Iron Bioresorbable
Peripheral Scaffold System and IBS Angel™ were approved in the United States by
the FDA for "Compassionate Use", and
IBS™ Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System obtained the
implied permission for conducting confirmatory clinical trials in China.
Meanwhile, the total of 1,350 patent applications have been filed, of which 496
patents have been registered as at 30 June 2021, which is an important
intangible asset and an internal driving force of LifeTech improving its core
competitiveness in the global device market.
Source: LifeTech Scientific Corporation
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。